Patient Recruitment/Retention Featured Articles

  1. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  2. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.

  3. Making Medical Innovation Matter To Patients With Simplified Trial Design 1/9/2026

    To be a leader in today’s environment, Lexicon Pharmaceuticals CMO Craig Granowitz, MD, Ph.D., says companies must embrace simplified clinical trial designs, which can reduce regulatory risks, lower R&D costs, and shorten clinical timelines.

  4. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

  5. FDA Further Expands And Clarifies Expanded Access FAQs 12/29/2025

    Healthcare attorney Dianne J. Bourque breaks down the FDA's October 2025 update to its Expanded Access FAQs.

  6. 2 Expectations & 2 Warnings For The Year Ahead 12/19/2025

    Just when I thought I was done with 2026 predictions for the clinical trial industry, three members of my editorial board emailed me some great ones, hence, part 3 of this series. What’s interesting is that two of these submissions, coincidentally, are focused on optimism for AI. In contrast, Denise Bronner’s forecast for the coming year is much more … well, dire.

  7. Most Ex-U.S. Countries Can't Access The Medicines They Help Study 12/19/2025

    When a country hosts a clinical trial, we assume patients there will eventually benefit from the therapy they helped test. Research Jennifer E. Miller, Ph.D., says that's not often the case.

  8. More 2026 Clinical Predictions 12/17/2025

    Part 2 of this 2026 forecast series dives deeper into the operational friction points the clinical trials industry still hasn’t resolved. Industry leaders weigh in on sponsor–site partnerships under strain, the growing tech burden on sites, consolidation across site networks and platforms, the limits of AI hype, and why human connection may end up being the most important “innovation” of all.

  9. The Site Perspective: Why Ambient AI Is The Missing Link In Clinical Trial Data Integrity 12/10/2025

    Discover how AI ambient listening has changed the way Mikel Daniels, DPM, MBA, and his team conduct clinical research at WeTreatFeet Podiatry. 

  10. Takeda Keeps Patients The Focus Of PDTs For Rare Disease 12/9/2025

    Takeda’s Kristina Allikmets, MD, Ph.D, shares how her team incorporates patient voices and prioritizes innovations to reduce treatment burden, expand access, and develop plasma-derived therapies for rare diseases.